Validation of the reconstituted high-density lipoprotein (rHDL) drug delivery platform using dilauryl fluorescein (DLF)

Drug Delivery and Translational Research
Walter J McConathyAndras G Lacko

Abstract

Dilauryl fluorescein (DLF) is a lipid soluble molecule that becomes fluorescent when lauric acid is removed by hydrolysis The purpose of these studies was to evaluate DLF as a potential probe for the function of reconstituted high-density lipoproteins (rHDL) as hydrophobic drug transport vehicles. The DLF containing rHDL nanoparticles were characterized regarding their physical/chemical properties, including molecular diameter, molecular weight, chemical composition, and buoyant density. We investigated the uptake of DLF from rHDL in cells that overexpress the scavenger receptor (SR-B1), known to facilitate the selective cellular uptake of cholesteryl esters from HDL. These studies show that DLF can be incorporated into rHDL and redistributed in the plasma compartment. In addition, these studies demonstrated an enhanced uptake and hydrolysis of DLF from rHDL by cells that overexpress the SR-B1 receptor, suggesting the involvement of a receptor mediated mechanism. The incorporation of DLF into the rHDL nanoparticles appear to protect against hydrolysis in the systemic circulation based on the lower rate of rHDL/DLF hydrolysis compared with the free DLF during incubation with human plasma. DLF may thus be used as a probe to track...Continue Reading

References

Jan 1, 1970·Advances in Protein Chemistry·G K Ackers
Oct 1, 1982·Journal of Medicinal Chemistry·R E Counsell, R C Pohland
Jul 29, 1999·American Journal of Therapeutics·W W LoneyA G Lacko
Mar 7, 2001·Frontiers in Bioscience : a Journal and Virtual Library·S YamashitaY Matsuzawa
Mar 8, 2002·Atherosclerosis·Jerzy-Roch NoferArnold von Eckardstein
Feb 8, 2003·Atherosclerosis. Supplements·P J Barter
Aug 16, 2003·Arteriosclerosis, Thrombosis, and Vascular Biology·Bernardo L TrigattiAttilio Rigotti
Mar 26, 2004·The Journal of Adolescent Health : Official Publication of the Society for Adolescent Medicine·Ximena Urrutia-RojasWalter McConathy
Apr 15, 2004·International Journal of Pharmaceutics·Junzo SekiTadanori Mayumi
Jun 25, 2005·Circulation Research·Gary F Lewis, Daniel J Rader
Nov 5, 2005·Arteriosclerosis, Thrombosis, and Vascular Biology·Linda K CurtissKerry-Anne Rye
May 13, 2006·Chemotherapy·Andras G LackoWalter J McConathy
Nov 1, 2007·Expert Opinion on Drug Delivery·Andras G LackoWalter J McConathy
Jan 1, 2007·Recent Patents on Drug Delivery & Formulation·András G LackóWalter J McConathy
Jul 30, 2009·Journal of Drug Targeting·Linda K MooberryAndras G Lacko
Mar 5, 2010·Current Pharmaceutical Design·Illiana MeursTheo J C Van Berkel

❮ Previous
Next ❯

Citations

Jul 28, 2012·Therapeutic Delivery·Nirupama Sabnis, Andras G Lacko
Jan 7, 2016·Journal of Photochemistry and Photobiology. B, Biology·Sunil ShahIgnacy Gryczynski
Oct 13, 2016·Frontiers in Pharmacology·Maneesha A Rajora, Gang Zheng
Jun 20, 2018·Cancer Chemotherapy and Pharmacology·Mohammad MahmoudianAhmad Yari Khosroushahi
Oct 31, 2018·Frontiers in Pharmacology·Sangram RautAndras Lacko

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.